NICE TAs

05/08/2020

TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation

05/08/2020

TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (replaced TA296)

05/08/2020

TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant

05/08/2020

TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people

05/08/2020

TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder

05/08/2020

TA509:Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

05/08/2020

TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen

05/08/2020

TA297: Ocriplasmin for treating vitreomacular traction

29/07/2020

TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

29/07/2020

TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis

29/07/2020

TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis

29/07/2020

TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

29/07/2020

TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis

29/07/2020

TA401: Bosutinib for previously treated chronic myeloid leukaemia (replaced TA299)

29/07/2020

TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation

29/07/2020

TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

29/07/2020

TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

29/07/2020

TA340: Ustekinumab for treating active psoriatic arthritis (replaced TA313)

28/07/2020

TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia

28/07/2020

TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (replaced TA376)